ReviewCurrent hypertension reports2026
Patient Selection and Renal Denervation.
Review in Current hypertension reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewTo review the current data informing patient selection and provide guidance on when to refer potential patients for consideration of renal denervation. RECENT
findingsMultiple sham-controlled randomized trials have demonstrated favorable safety and efficacy outcomes for renal denervation (RDN) in the management of uncontrolled hypertension in patients across the hypertension (HTN) spectrum including patients with true resistant hypertension (TRH) and in patients both on and off antihypertensive therapy. In addition, sustained reductions in BP up to 3 years have been observed. Based on these favorable findings, guidelines and position papers recommend RDN as an adjunct to antihypertensive medications and lifestyle modifications in patients with uncontrolled hypertension and increased risk of cardiovascular (CV) complications like TRH patients and in patients who are unable or unwilling to optimize medical therapy for uncontrolled hypertension. However, data on RDN safety and efficacy remain limited in chronic kidney disease (CKD) and isolated systolic hypertension (ISH). Another area of active investigation is the identification of predictors of response to RDN which could help refine criteria for patient selection. Selection of patients for RDN requires an evaluation of the hypertension prior to referral in addition to engaging patients in shared decision-making (SDM). It is also recommended that patients being considered for RDN be evaluated by a multidisciplinary team who is knowledgeable about hypertension and RDN. RDN is an adjunct to lifestyle modification and medications for the treatment of hypertension. Appropriate patient selection for RDN is based on populations studied in clinical trials and should include a comprehensive evaluation of the uncontrolled hypertension prior to referral.
Indexed as
Identifiers
41563656What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.